Table 3.
Results from multivariate linear regression final models to identify factors associated with the relative change in bilirubin over the first 12 weeks of ATV treatment
| Relative change in bilirubin | 95% Confidence Interval | P-value | |
|---|---|---|---|
|
Main model – with HCV seropositivity |
|
|
|
| Baseline ALP (/5 IU increase) |
0.99 |
0.98, 1.00 |
0.04 |
| TDF use at baseline |
0.86 |
0.72, 1.00 |
0.10 |
| HCV seropositivity |
0.80 |
0.66, 0.97 |
0.02 |
| Baseline bilirubin |
0.98 |
0.96, 1.00 |
0.05 |
|
Sensitivity analysis 1 – with methadone use |
|
|
|
| ALP at baseline (/5 IU increase) |
0.99 |
0.98, 1.00 |
0.01 |
| TDF use at baseline |
0.83 |
0.70, 0.99 |
0.04 |
| Methadone use |
0.77 |
0.65, 0.92 |
0.01 |
| Baseline bilirubin |
0.98 |
0.96, 1.00 |
0.04 |
|
Sensitivity analysis 2 – with IVDU |
|
|
|
| ALP at baseline (/5 IU increase) |
0.99 |
0.98, 1.00 |
0.02 |
| TDF use at baseline |
0.83 |
0.70, 1.00 |
0.05 |
| IVDU |
0.85 |
0.70, 1.00 |
0.08 |
| Baseline bilirubin | 0.98 | 0.96, 1.00 | 0.02 |